MicroRNA as an Early Biomarker of Neonatal Sepsis

Jouza, Martin; Bohošová, Júlia; Stanikova, Andrea; Pecl, Jakub; Slabý, Ondřej; Jabandžiev, Petr

doi:10.3389/fped.2022.854324

Cited by 16 publications

(9 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, these results most certainly cannot be directly extrapolated to neonatal patients with sepsis due to the widely different conditions, age, developmental stage, and overall state of the organism struck by neonatal sepsis ( 28 ). To the best of our knowledge, this present meta-analysis is the first reported investigation of the diagnostic value of suPAR in neonatal sepsis.…”

Section: Discussionmentioning

confidence: 99%

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

Chen

Wang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundNeonatal sepsis is one of the major causes of morbidity and mortality in newborns. However, atypical clinical manifestations and symptoms make the early diagnosis of neonatal sepsis a challenge. Relatively high-serum soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated as a diagnostic biomarker for adult sepsis. Therefore, the meta-analysis is intended to explore the diagnostic value of suPAR for neonatal sepsis.MethodsThe PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, China Biological Medicine Disk, and Wanfang databases were retrieved from inception to 31 December 2022 to collect diagnostic accuracy studies about suPAR for neonatal sepsis. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias in the included studies using the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool. Then, a meta-analysis was performed using Stata 15.0 software.ResultsA total of six articles involving eight studies were included. The results of the meta-analysis showed that the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.89 [95%CI (0.83–0.93)], 0.94 [95%CI (0.77–0.98)], 14 [95%CI (3.5–55.2)], 0.12 [95%CI (0.08–0.18)], and 117 [95%CI (24–567)], respectively. The area under the curve (AUC) of summary receiver operator characteristic (SROC) curves was 0.92 [95%CI (0.90–0.94)]. Sensitivity analysis confirmed the stability of the results, and publication bias was not observed. Fagan’s nomogram results demonstrated the clinical availability of the findings.ConclusionCurrent evidence suggests that suPAR has potential diagnostic value for neonatal sepsis. Owing to the limited quality of the included studies, more high-quality studies are needed to verify the above conclusion.

show abstract

Section: Discussionmentioning

confidence: 99%

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

Chen

Wang

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…is was consistent with our study. ere have been many research studies looking for markers for the diagnosis and treatment of sepsis, including microRNAs, long noncoding RNAs, circular RNAs, pancreatic stone protein, and lipopolysaccharide-binding protein [26][27][28][29][30]. In our research, we identified 15 major hub genes (CCL5, CCR7, CD2, CD27, CD274, CD3D, GNLY, GZMA, GZMH, GZMK, IL2RB, IL7R, ITK, KLRB1, and PRF1) in the PPI network, and all of them were downregulated genes in sepsis.…”

Section: Discussionmentioning

confidence: 99%

Screening of Sepsis Biomarkers Based on Bioinformatics Data Analysis

Liang

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Background and objectives. Sepsis is a life-threatening organ dysfunction caused by the imbalance of the body’s response to infection. Delay in sepsis diagnosis has become a primary cause of patient death. This study aims to identify potential biomarkers of sepsis based on bioinformatics data analysis, so as to provide new gene biomarkers for the diagnosis and treatment of sepsis. Methods. Gene expression profiles of GSE13904, GSE26378, GSE26440, GSE65682, and GSE69528 were obtained from the National Center for Biotechnology Information (NCBI). The differentially expressed genes (DEGs) were searched using limma software package. Gene Ontology (GO) functional analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed to elucidate molecular mechanisms of DEGs and screen hub genes. Results. A total of 108 DEGs were identified in the study, of which 67 were upregulated and 41 were downregulated. 15 superlative diagnostic biomarkers (CCL5, CCR7, CD2, CD27, CD274, CD3D, GNLY, GZMA, GZMH, GZMK, IL2RB, IL7R, ITK, KLRB1, and PRF1) for sepsis were identified by bioinformatics analysis. Conclusion. 15 hub genes (CCL5, CCR7, CD2, CD27, CD274, CD3D, GNLY, GZMA, GZMH, GZMK, IL2RB, IL7R, ITK, KLRB1, and PRF1) have been elucidated in this study, and these biomarkers may be helpful in the diagnosis and therapy of patients with sepsis.

show abstract

“…These characteristics explain why attempts to use TNF as an early marker of sepsis have failed. Generally, the determination of cytokines a few hours after infection initiation reveals high IL-6 values, whereas TNF is no longer detectable [ 185 ].…”

Section: Biomarkers Presently Used In Clinical Practicementioning

confidence: 99%

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going

Boscarino,

Migliorino,

Carbone

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Neonatal sepsis is a bacterial bloodstream infection leading to severe clinical manifestations frequently associated with death or irreversible long-term deficits. Antibiotics are the drug of choice to treat sepsis, regardless of age. In neonates, the lack of reliable criteria for a definite diagnosis and the supposition that an early antibiotic administration could reduce sepsis development in children at risk have led to a relevant antibiotic overuse for both prevention and therapy. The availability of biomarkers of neonatal sepsis that could alert the physician to an early diagnosis of neonatal sepsis could improve the short and long-term outcomes of true sepsis cases and reduce the indiscriminate and deleterious use of preventive antibiotics. The main aim of this narrative review is to summarize the main results in this regard and to detail the accuracy of currently used biomarkers for the early diagnosis of neonatal sepsis. Literature analysis showed that, despite intense research, the diagnosis of neonatal sepsis and the conduct of antibiotic therapy cannot be at present decided on the basis of a single biomarker. Given the importance of the problem and the need to reduce the abuse of antibiotics, further studies are urgently required. However, instead of looking for new biomarkers, it seems easier and more productive to test combinations of two or more of the presently available biomarkers. Moreover, studies based on omics technologies should be strongly boosted. However, while waiting for new information, the use of the clinical scores prepared by some scientific institutions could be suggested. Based on maternal risk factors and infant clinical indicators, sepsis risk can be calculated, and a significant reduction in antibiotic consumption can be obtained.

show abstract

MicroRNA as an Early Biomarker of Neonatal Sepsis

Cited by 16 publications

References 75 publications

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

Screening of Sepsis Biomarkers Based on Bioinformatics Data Analysis

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going

Contact Info

Product

Resources

About